Brain Cancer – Tackling the Intractable: Novel Targets and Approaches

Moderator: Minesh P. Mehta, MD, Medical Director, Maryland Proton Treatment Center, University of Maryland Panelists: Lauren Abrey, MD, Oncology Development Site Head, F. Hoffmann-La Roche Inc. Thomas Davis, MD, CMO and SVP Clinical Development, Celldex Therapeutics H. Ian Robins, MD, PhD, Faculty, University of Wisconsin School of Medicine and Public Health Eric Rowinsky, MD, Chief […]

New Treatment Options for Prostate Cancer

After decades of incremental progress, at best, in treating advanced prostate cancer, men with androgen independent disease now have many different treatment options. Since 2010, 5 new drugs representing 4 different treatment strategies that offer not only symptom relief, but also longer survival, have been approved by the FDA. Furthermore, stimulated by this success, there […]

Evidentiary Standards for Diagnostics: When does a Biomarker become a Diagnostic for Cancer Treatment?

In both community and academic cancer centers there is a rapid adoption of NGS and other multiplex platforms to interrogate the biology of an individual’s tumor. For each individual patient, vast amounts of data are being generated, annotated with identification of “actionable” targets for therapeutic intervention. The level of evidence for these target-directed therapies ranges from […]